FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and INTESTINAL PERFORATION
See full prescribing information for complete boxed warning.
- TRADE NAME: Zydelig (Gilead)
- INDICATIONS: Relapsed chronic lymphocytic leukemia (with rituximab), follicular B-cell non-Hodgkin lymphoma, small lymphocytic lymphoma
- CLASS: Phosphoinositide 3-kinase (Phosphatidylinositol 3-kinase) (PI3K) inhibitor
- HALF-LIFE: 8 hours
- FDA APPROVAL DATE: 07/23/2014
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Carbamazepine, Copanlisib, Midostaurin, Neratinib, Phenytoin, Rifampin, St John's Wort, Strong CYP3A inducers and substrates
- See adverse reactions attributed to class:
Phosphoinositide 3-kinase (Phosphatidylinositol 3-kinase) (PI3K) inhibitor
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
